IMR Press / EJGO / Volume 38 / Issue 1 / DOI: 10.12892/ejgo3190.2017

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Original Research
Can preoperative neutrophil to lymphocyte and platelet to lymphocyte ratios predict cervical stromal involvement in endometrioid endometrial adenocarcinoma?
Show Less
1 Department of Gynecology and Obstetrics, Cerrahpasa Faculty of Medicine, Istanbul University, Fatih, Istanbul, Turkey
2 Uniklinikum Oldenburg, Oldenburg, Germany
Eur. J. Gynaecol. Oncol. 2017, 38(1), 20–24;
Published: 10 February 2017

Purpose: To evaluate the possible relationships between preoperative inflammatory markers [neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR)] and cervical stromal involvement in endometrioid endometrial adenocarcinoma. Materials and Methods: Charts and pathology results of 639 women who were operated on for endometrioid endometrial adenocarcinoma between 2000 and 2013 in the present clinic were retrospectively reviewed. Demographic, laboratory, and clinical parameters were evaluated. Results: 118 women (18.4%) had cervical stromal involvement. Lymph node positivity was significantly more frequent in the cervical stromal involvement group (p < 0.001). A threshold value of 2.41 for NLR had a sensitivity of 62.7%, specificity of 60.1%, PPV of 61.1%, and NPV of 61.8% for the presence of cervical stromal involvement. In multivariate analysis, increased NLR had a significant predictive value for cervical stromal involvement (p = 0.006, OR = 2.03), although PLR remained non-significant (p = 0.77, OR = 1.08). Conclusions: The preoperative NLR assessment is a significant predictor for cervical stromal involvement in endometrioid endometrial adenocarcinoma.
Neutrophil to lymphocyte ratio
Platelet to lymphocyte ratio
Cervical stromal involvement
Endometrioid adenocarcinoma
Back to top